. Author manuscript; available in PMC: 2008 May 2.

Published in final edited form as: J Subst Abuse Treat. 2007 Feb 22;32(4):321–329. doi: 10.1016/j.jsat.2006.05.021

Table 1.

Descriptive Statistics

Variable	Outside CTN (n=766)	Within CTN (n=240)	Significance (p)
Adopted buprenorphine^a	11.1	20.0	<.001
Adopted motivational incentives^a	31.2	33.8	ns
Operating revenues from public sources (M)	47.8	51.9	ns
For-profit structure	17.9	12.4	<.029
Accredited by JCAHO or CARF	48.1	65.6	<.001
Surveys buyers, suppliers, or both	77.3	70.1	<.016
Offers detoxification services	29.1	18.6	<.001
Outpatient-only services	46.9	52.7	ns
FTEs (M)	34.0	33.7	ns
Physician(s) on staff or contract	69.3	71.8	ns
Master's level counselors	44.5	44.5	ns
Primary opiate clients^b	15.9	41.8	<.000
Program experience in clinical research	41.7	41.1	ns

Adoption of buprenorphine and incentives was measured on 6-month follow-up interview. All other variables were measured at baseline interview.

Removal of methadone units from CTN sample reduced the average opiate clients to 18.3% of CTN caseloads, which is still significantly higher than in non-CTN settings (p<.05).